Just the FACTs 2021 Volume 5

Posted in :: 2021 Volume 5 :: Tuesday, October 26th, 2021

The past few years have brought many dramatic changes in cellular therapy, but some things never change. FACT’s deep appreciation for collegial, peer-to-peer collaboration remains, and has been a bedrock to our organization as we navigate challenges and opportunities. To that end, FACT is continuing to evolve as evidenced by the recent review and revision of our Bylaws by FACT’s Board of Directors to keep pace with the ever-expanding cell therapy field!

In this newsletter, articles do not necessarily announce “new” concepts, but reaffirm our commitment to principles we have long supported. Quality management principles, regulatory compliance, and interorganizational initiatives are here to stay at FACT. We review donor eligibility requirements for donor lymphocyte infusions, describe the Circular of Information for the Use of Cellular Therapy Products, explain outcome analysis requirements for new cellular therapy products, and renew our commitment to ISBT 128 coding and labeling. FACT continues to be a criterion for U.S. News & World Report’s Best Hospitals List, an inspiring partner for World Cord Blood Day, and supportive of related organizations’ efforts. We also want to acknowledge the election of one of our past Presidents, Dr. Helen Heslop, to the National Academy of Medicine!

We heard on many occasions how FACT accreditation has helped cellular therapy programs and cord blood banks navigate the COVID-19 pandemic and grow along with advances in the field. As we look to the future, we can feel confident in our ability to handle new developments because of our rich history of achieving FACT accreditation together.


Catherine Bollard, MD
FACT President